CD8A and graft versus host disease: Our objectives included eliminating TCR expression and finely tuning MHC-I silencing, thereby preventing graft-versus-host disease (GvHD) and ensuring balanced protection from host CD8 T cell- and natural killer (NK) cell-mediated immune rejection.